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The British Thoracic Society (BTS) Guidelines for Bronchiectasis in adults were published in January 2019, and comprise
recommendations for treatment from primary to tertiary care. Here, we outline the practical implications of these guidelines for
primary care practitioners. A diagnosis of bronchiectasis should be considered when a patient presents with a recurrent or
persistent (>8 weeks) productive cough. A deﬁnitive diagnosis is made by using thin-section chest computed tomography (CT).
Once diagnosed, patients should be initially assessed by a specialist respiratory team and a shared management plan formulated
with the patient, the specialist and primary care teams. The cornerstone of primary care management is physiotherapy to improve
airway sputum clearance and maximise exercise capacity, with prompt treatment of acute exacerbations with antibiotics.
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INTRODUCTION
Bronchiectasis is a condition where patients have symptoms of
persistent or recurrent bronchial sepsis related to irreversibly
damaged and dilated bronchi.1 The incidence and prevalence of
bronchiectasis is rising. Using the Clinical Practice Research
Datalink (CPRD) in the United Kingdom, patients 18 and over
with a Read code of Bronchiectasis were identiﬁed, and the point
prevalence in February each year from 2004 to 2013 was
measured. This showed that the point prevalence of coded
bronchiectasis rose from 351 to 566 per 100,000 in women and
from 301 to 486 per 100,000 in males between 2004 and 2013.2 A
retrospective study using healthcare data from the United States
showed a rise in prevalence of 8% between 2001 and 2012, but
with a point prevalence of 139/100,000.3 The British Thoracic
Society (BTS) Guideline for non-cystic ﬁbrosis (non-CF) bronch-
iectasis was published in 20104 and included children. The BTS
commissioned an update to the guidelines in 2013 to take into
account any new evidence. The new BTS Guideline covers
bronchiectasis in adults and provides recommendations and good
practice points based on an updated evidence review.1
Systematic electronic database searches of relevant literature
were carried out in June 2014 and June 2016, identifying relevant
papers published since the previous guideline. In total, 1799 such
papers were identiﬁed and reviewed by pairs of Guideline
Committee members. Appraisal of the evidence was carried out
based on Scottish Intercollegiate Guidelines Network (SIGN)
methodology, as set out in the BTS Guideline Production Manual.5
The reliability of the evidence in each individual study was graded,
using the SIGN critical appraisal checklists and levels of evidence
assigned to evidence statements, according to the levels of
evidence in Table 1.5,6 Recommendations made by the Guideline
Committee were formulated based on the evidence statements
and graded according to the SIGN grading system (Table 2).6
The composition of the Guideline Committee and the
subsequent guideline recommendations were biased towards
secondary care. One member of the Guideline Committee (KGJ—
lead author of this paper) was from primary care. This paper
acknowledges this and with ﬁve primary care authors aims to look
at the relevance of the guidelines for primary care.
INITIAL PRESENTATION OF BRONCHIECTASIS
A diagnosis of bronchiectasis should be suspected when a patient
presents with a recurrent or persistent (>8 weeks) cough, with
production of purulent or mucopurulent sputum, particularly with
the relevant associated risk factors, such as COPD. This diagnosis is
particularly likely if the patient has a history of two or more COPD
exacerbations per year and a previous positive sputum sample for
Pseudomonas aeruginosa whilst stable (i.e. not during an
exacerbation).1
A meta-analysis of six observational studies of 881 patients,
mainly based on secondary care, found that the prevalence of
bronchiectasis was 54.3% in patients with COPD.7 One study
conducted in 110 patients from 29 UK general practices showed
that the prevalence of bronchiectasis was 29% in patients with
COPD.8 Patients with bronchiectasis and COPD had a lower FEV1-
weighted mean difference (WMD)—8%, more frequent exacerba-
tions (WMD 1.54 times more in the previous year) and 7.33 times
more likely to have persistent sputum pathogens, especially P.
aeruginosa than COPD patients without bronchiectasis.7
In addition to coincident presentation with COPD, a diagnosis of
bronchiectasis should be suspected in patients presenting with
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persistent cough, who also report difﬁcult-to-treat asthma,9
rheumatoid arthritis,10 inﬂammatory bowel disease (IBD),11
chronic rhinosinusitis12 or the presence of persistent sputum
pathogens, especially P. aeruginosa.1
HISTORY, EXAMINATION AND INVESTIGATIONS
If bronchiectasis is suspected in a patient in a primary care setting,
a full medical history and examination should be ﬁrst directed to
exclude other causes of cough, such as COPD, lung cancer, asthma
and gastro-oesophageal reﬂux. Persistent basal, coarse lung
crackles may be present.
Investigations in the primary care setting should encompass:
● Diagnostic spirometry to look for other/coexistent diagnoses
(such as COPD) and may be normal, restrictive or obstructive.
● Sputum microbiology is helpful in identifying the presence of
persistent pathogens, especially P. aeruginosa (indicating a
worse prognosis).
● A chest X-ray should be carried out to help exclude alternative
diagnoses, but has limited sensitivity for diagnosing bronch-
iectasis, especially in mild disease.
● Deﬁnitive diagnosis of bronchiectasis is made, using thin-
section CT scanning of the chest. It is highly accurate and
diagnostic for bronchiectasis, with false-positive and false-
negative rates of 1% and 2%, respectively.13 Referral for CT will
usually be made via a secondary care specialist, although
some primary care practitioners may have direct access.
Figure 1 shows a suggested diagnostic algorithm by the authors
of this article for patients suspected of having bronchiectasis in
primary care.
ASSESSMENT AND ROUTINE
It is recommended that the initial assessment after diagnosis of
bronchiectasis is carried out by a specialist respiratory team,
where investigations can take place to elucidate any underlying
cause and to formulate a treatment plan, which can be shared
with the patient, primary care team and community team where
appropriate. Single-centre studies suggest that investigations into
the underlying cause of bronchiectasis can change management
in 5–37% patients.14
The underlying causes can include conditions such as allergic
bronchopulmonary aspergillosis, immune deﬁciency, cystic ﬁbro-
sis (in relevant patients) and non-tubeculous mycobacterial (NTM)
disease.14,15 Co-morbid conditions should be assessed, including
asthma, COPD, gastro-oesophageal reﬂux disease (GORD), rheu-
matoid arthritis and inﬂammatory bowel disease, and treated
accordingly.
The treatment plan should give details of treatment in the
stable condition, advice on treatment in the event of an acute
exacerbation and arrangements for follow-up (primary care,
hospital care and shared care). See Fig. 2 for a suggested checklist
as part of the algorithm for review and management of patients
wth bronchiectasis in primary care.
ROUTINE REVIEW
Patients at higher risk of future exacerbations should be reviewed
in specialist care, where they present with or develop one or more
of the following clinical situations:1
● They experience three or more exacerbations in 1 year.
● They have chronic Pseudomonas aeruginosa, non-tuberculous
Table 1. SIGN levels of evidence5,6
Grade Evidence
1++ High-quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews of RCTs or RCTS with a low risk of bias
1− Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of bias
2++ High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with a very low risk of
confounding, bias or chance and a high probability that the relationship is casual
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship
is casual
2− Case–control or cohort studies with a high risk of confounding, bias or chance and a signiﬁcant risk that the relationship is not casual
3 Non-analytic studies, for example, case reports and case series
4 Expert opinion
RCT randomised control trial
Table 2. SIGN grades of recommendation5,6
Grade Type of evidence
A At least one meta-analysis, systematic review or RCT rated as 1++ and directly applicable to the target population or a systematic review of
RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall
consistency of the results
B A body of evidence, including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of the
results or extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence, including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of the
results or extrapolated evidence from studies rated as 2++
D Evidence of level 3 or 4 or extrapolated evidence from studies rated as 2+
√ Important practical points for which there is no research evidence, nor is there likely to be any research evidence. The guideline committee
wishes to emphasise these good practice points
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mycobacteria (NTM) or methicillin-resistant Staphylococcus
aureus (MRSA) colonisation.
● There is deteriorating bronchiectasis with declining lung
function.
● They have associated rheumatoid arthritis, immune deﬁciency,
inﬂammatory bowel disease or primary ciliary dyskinesia.
● They have allergic bronchopulmonary aspergillosis.
● Patients with advanced disease and those considering lung
transplantation.
Lower-risk patients can be routinely reviewed in primary care.
The exact frequency of review should be determined in the initial
treatment plan, in consultation with the respiratory specialist and
also by changing clinical conditions, but should be at a minimum
frequency of once a year.
Factors to be routinely monitored by the primary care team (see
Fig. 2) include:
● Assessment of symptoms (cough, sputum production and
breathlessness) and their impact on daily activities.
● Chronic cough that can have a signiﬁcant effect on daily
activities, including sexual relations and urinary incontinence
in women.16
● Exacerbation frequency.
● Body mass index (BMI).
● Pulse oximetry.
● Spirometry.
● The sputum should be sent for microbiological analysis when
the patient is clinically stable, and should be sent at the start
of an exacerbation before antibiotic treatment is started.1
● Compliance with sputum clearance exercises and shared
treatment plan.
Deterioration in lung function, exacerbation frequency or
clinical state should prompt specialist referral (see above). If the
patient’s BMI is <20 kg/m2, then specialist nutritional advice
should be sought. In addition, the patient should be referred to a
respiratory physiotherapist to reinforce the sputum clearance
exercises if necessary. Similarly, referral for pulmonary rehabilita-
tion should be considered, if the patient has functionally disabling
breathlessness (MRC score ≥ 2).
Common co-morbidities, such as mild-to-moderate asthma or
COPD, can be treated in the primary care setting, according to
national or international guidelines for these conditions.17–20 It is
recommended that chronic rhinosinusitis be treated with nasal
saline douching and intranasal steroids. There is a strong
association between bronchiectasis and gastro-oesophageal dis-
ease (GORD) and patients with GORD have a more severe
disease.21 The guideline recommends that symptoms of GORD
are speciﬁcally sought out and treated, according to the existing
NICE guidance, but do not provide evidence that treatment of
GORD will improve bronchiectasis outcomes.
MANAGEMENT
The overall aims of management are to prevent further damage
(treat the underlying cause if possible), maximise function and
quality of life and prevent and treat exacerbations. Figure 3 shows
a stepwise approach to management.1
PHYSIOTHERAPY
All patients with bronchiectasis should be assessed by a
respiratory physiotherapist. Chest physiotherapy can mobilise
Fig. 1 Proposed algorithm for the diagnostic pathway in primary care of patients suspected of having bronchiectasis
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secretions and aid effective expectoration,22–24 providing
improvement in cough scores. Table 3 shows the key elements
of physiotherapy intervention.
INFLUENZA AND PNEUMOCOCCAL IMMUNISATION
It is important to offer annual inﬂuenza immunisation to all
patients with bronchiectasis.25 In addition, the guidelines recom-
Fig. 2 Proposed algorithm for the review and management of patients with bronchiectasis in primary care
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mend that polysaccharide pneumococcal vaccination should be
offered to all patients with bronchiectasis (if not previously given),
although this recommendation comes from evidence that 23
valent pneumococcal vaccinations can reduce the risk of all-cause
pneumonia.26
INHALED CORTICOSTEROIDS AND BRONCHODILATORS
Treatment with inhaled corticosteroids (ICS) in bronchiectasis is
not recommended, unless the drug is needed for comorbid
diseases, such as asthma or COPD, according to treatment
guidelines.17–20 A Cochrane review showed that treatment with
ICS demonstrated a minimal reduction in sputum volume, but no
effect on exacerbations.27 The studies included in the article used
a relatively high dose of ICS (≥ 800mcg of beclometasone
equivalent) and there was a high incidence of local and systemic
side effects. It is recommended to offer a trial of long-acting
inhaled bronchodilators in patients with signiﬁcant breathlessness
or where there is coexistent asthma and/or COPD.1
No evidence was found for the use of short-acting beta-2
agonists and limited evidence for long-acting beta-2 agonists
(LABA) and long-acting anti-muscarinic agents (LAMA).28 Use of
LABA and LAMA is recommended in patients with signiﬁcant
breathlessness and coexistent obstructive airway disease of
whatever aetiology.
LONG-TERM ANTIBIOTIC THERAPY
Long-term—3 months or more—antibiotic therapy should be
considered for patients with three or more exacerbations per year,
which should be initiated and monitored by specialist teams in
secondary care. Treatment with oral azithromycin, 250mg, three
times weekly for a year can reduce the incidence of exacerbations
in patients with bronchiectasis,29 and this is recommended as a
pragmatic starting dose in the guidelines.1 In patients with
concurrent P. aeruginosa infection, the recommended ﬁrst-line
therapy is inhaled colistin. Sputum samples from a secondary care
population show that H. inﬂuenzae and P. aeruginosa are the most
common bacterial isolates with other pathogens, such as M.
catarrhalis, S. pneumoniae and non-tuberculous mycobacteria also
being found.30 The presence of P. aeruginosa not only guides the
choice of antibiotic therapy, but also signiﬁes a worse prognosis
with a threefold risk in mortality, higher risk of hospital admission
and poorer quality of life.31
MANAGEMENT OF THE ACUTE EXACERBATION
Where an acute exacerbation incident is suspected, the ﬁrst step
should be to assess the vital signs (pulse oximetry, pulse rate,
respiratory rate, temperature and blood pressure). In the primary
care setting, the patient should be treated for acute co-
morbidities, such as asthma and COPD, according to disease-
speciﬁc guidelines.17–20,32 The patient should be considered for
admission to a secondary care setting, where there are features of
sepsis or respiratory distress, where there are signiﬁcant co-
Step 1
- Treat underlying cause
- Airways clearance techniques
+/- pulmonary rehabilitation
- Annual influenza vaccination
- Prompt antibiotic treatment
for exacerbations
- Self-management plan
Step 2
If 3 or more 
exacerbations/yr
despite Step 1*
- Physiotherapy 
reassessment
and consider mucoactive
treatment
Step 3
If 3 or more exacerbations/yr
despite Step 2*
1. If Pseudomonas 
aeruginosa, long term inhaled
anti-pseudomonal antibiotic
or alternatively long term 
macrolide
2. If Other Potenitally P
Pathogenic Microorganisms,
long term macrolides or 
alternatively long term oral
or inhaled targeted antibiotic
3. If no pathogen, long term
macrolide 
Step 4
If 3 or more
exacerbations/yr
despite Step 3*
- Long term macrolide
and long term inhaled
antibiotic
Step 5
If 5 more 
exacerbations/yr
despite Step 4*
 - Consider regular
intravenous antibiotics
every 2–3 months
* Consider this step if significant symptoms persist despite previous step, 
even if not meeting exacerbation criteria
Antibiotics are used to treat exacerbations that present with an acute deterioration (usually over several days) with worsening local symptoms (cough,
increased sputum volume or change viscosity, increased sputum purulence with or without increasing wheeze, breathlessness, haemoptysis)
and/or systemic upset.
The flow diagram refers to three or more annual exacerbations
Fig. 3 Stepwise management of patients with bronchiectasis. Reproduced from ref. 1, with permission from BMJ Publishing Group Ltd.
Table 3. Key elements of physiotherapy in bronchiectasis
• Patients are taught to carry out airway clearance techniques, such as active cycle of breathing technique (ACBT)15 (or using an oscillating positive
expiratory pressure device, such as the “Flutter” and “Acapella”.16 This is tailored to the individual patient (usually once to twice daily) and may be
increased during an exacerbation.
• Airway clearance may be optimised using postural drainage (use of gravity-assisted positioning to drain areas of the lung) and prior inhalation of
isotonic or hypertonic saline.
• Consider a 6-month trial of mucolytic agents (such as oral carbocisteine) if there are continued difﬁculties with sputum expectoration.
• Pulmonary rehabilitation should be offered where a patient is functionally limited by breathlessness (MRC score ≥ 2).16
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morbidities and/or psychosocial factors or there is a need for
intravenous antibiotics, where a community service to provide
these is not available.
ACUTE ANTIBIOTIC THERAPY
Where possible, the sputum should be obtained for culture and
sensitivity testing prior to commencing antibiotics. However,
empirical antibiotics can be started whilst awaiting the sputum
results. Table 4 shows common organisms associated with acute
exacerbations of bronchiectasis and their treatment in primary
care. In general, antibiotic courses for 14 days are standard and
should always be used in patients infected with P. aeruginosa.
Shorter courses may sufﬁce in patients with mild bronchiectasis
(usually 7–10 days). It is recommended to consider providing a
home sputum pot and standby antibiotics for future
exacerbations.
PROGNOSIS
Patients with mild bronchiectasis should have a normal life
expectancy, but in patients with more-advanced bronchiectasis,
there is an increased risk of recurrent exacerbations, vascular
disease and mortality.30,31,33
CONCLUSIONS
A diagnosis of bronchiectasis should be suspected when a patient
presents with a persistent or recurrent productive cough. Deﬁnitive
diagnosis is made by thin-section CT scan of the chest. Assessment
of bronchiectasis should be carried out in secondary/tertiary care,
where a shared management plan should be formulated with the
patient and the community/primary care team.
Many patients can be routinely managed in primary care, where
the cornerstone of management is physiotherapy to improve
sputum clearance and maximise exercise capacity and prompt
treatment of exacerbations with antibiotics.
The British Thoracic Society Bronchiectasis Guidelines provide
advice for diagnosis and management of primary care in the
United Kingdom. Although some of the advice, such as the type of
antibiotics to be used, is speciﬁc to the United Kingdom, many of
the recommendations are in line with those of the European
Respiratory Society Guidelines 2017,34 and provide a sound basis
for primary care management of this increasingly prevalent
disease throughout the world.
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